CNBC's Meg Tirrell reports both Merck and Pfizer beat earnings expectations amid patent expirations.» Read More
Despite the recent meltdown in biotech, there are still areas of opportunity within the sector, Citi's Yaron Werber says.
Mallinckrodt is buying drug maker Questcor for $5.6 billion. Barbara Ryan, FTI Consulting managing director, discusses consolidation in pharmaceuticals and shares what stocks she likes in the space.
CNBC's Seema Mody and Dominic Chu look at what's behind today's massive market sell off including biotechs and online retailers.
Heather Bresch Mylan CEO, discusses the concern over capping drug prices and the impact of Obamacare on rising drug costs.
Jason Kolbert, head of health care research at Maxim Group, says that last week's biotech sell-off was not justified as the sector is going through a "paradigm shift" which should results in higher valuations.
Max Herrmann, partner and healthcare research analyst at Oriel Securities, said biotech stocks have gone through a correction after a "phenomenal" rally.
The U.S. government is prohibited by law from negotiating drug prices, reports CNBC's Sheila Dharmarajan.
CNBC's Sheila Dharmarajan discusses the beat down biotech stocks have recently taken and gives 3 reasons why investors should stick with the sector.
CNBC's Sheila Dharmarajan reports why analysts think investors should stick with the biotech sector.
Gilead received a letter from U.S. lawmakers questioning the pricing of its hepatitis c drug Solvadi. Mark Schoenebaum, ISI Health Care Research Group senior managing director, provides perspective.
CNBC's Jim Cramer shares his thoughts on yesterday's Nasdaq selloff and the slumping biotech sector.
Barbara Ryan, FTI Consulting, and Matt Maley, MillerTabek and Company, discuss what has propelled the massive sell-off in the biotech sector.
CNBC's Dominic Chu digs into the battered biotech sector and reveals which stocks are still sliding.
The FMHR traders discuss what warning signs bull investors should be looking for in the stock market and concerns about a biotech bubble.
U.S. lawmakers sent a letter to Gilead requesting information on pricing for its hepatitis c drug Sovaldi. Christopher Raymond of R.W. Baird.
Discussing the market's big reaction to news U.S. lawmakers requested information about Gilead's hepatitis C drug Sovaldi, and which stocks are attractive in the sector, with Geoff Porges, Bernstein Research senior analyst.
CNBC's Dominic Chu reports the health care sector is being dragged down by the biotech sector. Congressional Democrats asked biotech company Gilead to provide insight on pricing for its hepatitis C drug Sovaldi.
CNBC's Sheila Dharmarajan reports on the decline in the Nasdaq because of the hit to the biotechs. Gilead received a letter from senior Democrats requesting a briefing on the pricing for its hepatitis C drug Sovaldi.
MediWound develops treatments for severe burns and hard to heal wounds. Gal Cohen, MediWound CEO, discusses his company's medical solutions and the results of its IPO.
CNBC's Bob Pisani discusses the IPO of Castlight Health and how classic momentum stocks are trading, and CNBC's Sheila Dharmajan looks at what biotech stocks are getting hit hard.